newsfilter
← Latest News
PR Newswire·

RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease

Expect ARISE-4 Trial to Begin Around 2nd Quarter of 2023 ROCKVILLE, Md., Oct. 24, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug